Dr Reddy's Reviews Celevida GLP+ After FSSAI Notice
Dr. Reddy's Laboratories and Nestlé Health Science have initiated a comprehensive review of Celevida GLP+ claims and product branding. This internal evaluation follows formal regulatory action by the Food Safety and Standards Authority of India (FSSAI). Specifically, the regulator questioned promotional campaigns associating the specialized nutritional supplement with prescription anti-obesity medications. However, the regulatory body permitted ongoing commercial sales while leadership addresses the identified issues.
Regulatory Scrutiny Over Celevida GLP+ Claims
The food safety regulator highlighted concerns regarding marketing statements displayed across digital channels and retail packaging. Specifically, promotional copy claimed high-protein support for preserving lean muscle during GLP-1 and GIP receptor agonist therapies. Furthermore, the authorities found that the brand name itself created an improper therapeutic association with prescription medications. Regulators also noted that disclaimers failed to neutralize the impression of an approved medical adjunct. Consequently, the authorities directed stakeholders to justify these assertions under the Food Safety and Standards Act.
Implications for Clinical Practice and Patient Nutrition
Physicians increasingly prescribe GLP-1 receptor agonists to manage type 2 diabetes and clinical obesity. Consequently, patients experiencing rapid weight reduction frequently face substantial loss of skeletal muscle mass. Nutritional supplements can indeed help bridge targeted dietary protein deficits during medical weight loss programs. However, healthcare professionals must distinguish between validated medical foods and commercial dietary formulations. In addition, marketing supplements as complete meal replacements poses significant clinical concerns for patients requiring structured dietary guidance.
Next Steps for Dr. Reddy's and Nestlé Health Science
Leadership confirmed ongoing discussions with regulatory authorities to resolve branding and promotional concerns. MV Ramana, Executive Vice President at Dr. Reddy's, emphasized proactive engagement with the regulator. Additionally, the joint venture aims to adjust product labeling without disrupting consumer access in the market. Meanwhile, healthcare providers should evaluate patient dietary plans independently of commercial health representations. Therefore, clinicians must continue counseling patients on balanced whole-food nutrition alongside pharmacotherapy.
Frequently Asked Questions
Q1: Why did FSSAI issue a notice regarding Celevida GLP+?
The regulator flagged promotional claims suggesting muscle preservation during GLP-1 therapy and representations portraying the supplement as a meal replacement.
Q2: Can patients continue purchasing Celevida GLP+ during the review?
Yes, FSSAI permitted Dr. Reddy's and Nestlé Health Science to continue selling the product while reviewing branding and claims.
Q3: What clinical precautions should doctors observe regarding GLP-1 nutritional supplements?
Clinicians should independently assess patients' protein needs rather than relying on commercial claims that imply complete medical nutrition. For comprehensive guidance on managing metabolic conditions, practitioners can explore specialized clinical training through OC Academy.
References
- Dr Reddy’s reviews Celevida GLP+ brand name, advertising claims after FSSAInotice - ETHealthworld
- FSSAI issues notices to Dr Reddy's, Nestle, Flipkart over misleading ads - FNB News
- Dr. Reddy's and Nestlé Health Science launch Celevida GLP+ for people undergoing GLP-1/GIP therapy in India - Express Pharma
